# New Peer-Reviewed Publications Highlight Effectiveness of OMNI® Surgical System with TruSync™ Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans
Canonical URL: https://biopharmsignal.com/news/SGHT/new-peer-reviewed-publications-highlight-effectiveness-of-omnir-surgical-system-with-trusynctm-technology-in-reducing-iop-and-medication-usage-in-cataract-combination-procedures-standalone-procedures-and-in-african-americans
Ticker: SGHT
Company: Sight Sciences
Source: Sight Sciences
Published: 2025-11-11 12:00 EST
Original Source URL: https://investors.sightsciences.com
## Summary

Prospective study data and retrospective registry data were analyzed in the manuscripts recently published by the Journal of Cataract and Refractive Surgery, Journal of Glaucoma and Clinical Ophthalmology MENLO PARK, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc.

## Article Body
Prospective study data and retrospective registry data were analyzed in the manuscripts recently published by the Journal of Cataract and Refractive Surgery, Journal of Glaucoma and Clinical Ophthalmology MENLO PARK, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc.
## Recent Company News
- 2026-05-06 20:05 EST — [Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance](https://biopharmsignal.com/news/SGHT/sight-sciences-reports-first-quarter-2026-financial-results-and-raises-full-year-2026-revenue-guidance) — Source: Sight Sciences
- 2026-04-29 20:05 EST — [Sight Sciences to Present at Two Upcoming Investor Conferences](https://biopharmsignal.com/news/SGHT/sight-sciences-to-present-at-two-upcoming-investor-conferences) — Source: Sight Sciences
- 2026-04-22 20:45 EST — [Sight Sciences Announces the Release of its Sustainability Report](https://biopharmsignal.com/news/SGHT/sight-sciences-announces-the-release-of-its-sustainability-report) — Source: Sight Sciences
- 2026-04-21 20:05 EST — [Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026](https://biopharmsignal.com/news/SGHT/sight-sciences-to-report-first-quarter-2026-financial-results-on-may-6-2026) — Source: Sight Sciences
- 2026-04-01 20:05 EST — [Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting](https://biopharmsignal.com/news/SGHT/sight-sciences-interventional-technologies-for-glaucoma-and-dry-eye-disease-to-be-featured-in-multiple-clinical-presentations-at-the-2026-american-society-of-cataract-and-refractive-surgery-ascrs-annual-meeting) — Source: Sight Sciences
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)